DIMERx

DIMERx is an NIH-backed, clinical-stage biotech developing first-in-class, non-addictive pain therapeutics that treat pain without addiction or abuse. Our lead program, DMX-101, a peripherally acting buprenorphine dimer, offers a de-risked, late-stage asset addressing the $100 B global pain market—combining strong clinical validation, federal support, and rapid path to value creation.